Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Axsome Therapeutics

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

More than seven million people in the US are affected by the neurodegenerative disease

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

- PMLiVE

Roche shares promising data from Alzheimer’s disease development portfolio

The company is planning to initiate phase 3 studies of trontinemab in early AD this year

- PMLiVE

UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

It is hoped that the test could be available for widespread UK use in the coming years

- PMLiVE

Sanofi gains access to Alzheimer’s candidate through $470m Vigil acquisition

A phase 2 trial of the drug is expected to launch in the third quarter of this year

- PMLiVE

FDA approves Fujirebio’s Lumipulse as first Alzheimer’s disease blood test

The device offers a less invasive option compared to current PET scans and CSF tests

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

International Alzheimer’s disease prevention trial in at-risk young adults begins

The study will evaluate whether the amyloid beta protein can be blocked from ever accumulating in the brain

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

- PMLiVE

FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

The company hopes the revised protocol will accelerate the development timeline of buntanetap

- PMLiVE

Axsome announces positive results from phase 3 Alzheimer’s disease programme

The neurodegenerative disease affects approximately seven million people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links